Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Emmanuel B WalterKawsar R TalaatCharu SabharwalAlejandra C GurtmanStephen LockhartGrant C PaulsenElizabeth D BarnettFlor M MuñozYvonne MaldonadoBarbara A PahudJoseph B DomachowskeEric A F SimõesUzma N SarwarNicholas KitchinLuke CunliffePablo RojoErnest KucharMika RämetIona MunjalJohn L PerezRobert W FrenckEleni LagkadinouKena A SwansonHua MaXia XuKenneth KourySusan MatherTodd J BelangerDavid CooperÖzlem TüreciPhilip R DormitzerUğur ŞahinKathrin U JansenWilliam C Grubernull nullPublished in: The New England journal of medicine (2021)
A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).